Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical tr… Read more
Vivoryon Therapeutics N.V. (0R3M) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -1.413x
Based on the latest financial reports, Vivoryon Therapeutics N.V. (0R3M) has a cash flow conversion efficiency ratio of -1.413x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-4.50 Million) by net assets (€3.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Vivoryon Therapeutics N.V. - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Vivoryon Therapeutics N.V.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Vivoryon Therapeutics N.V. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vivoryon Therapeutics N.V. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MBT Bancshares Inc
PINK:MBKL
|
0.094x |
|
JHM Consolidation Bhd
KLSE:0127
|
-0.023x |
|
Ultimate Holdings Group Inc.
OTCGREY:UHGI
|
0.001x |
|
088340
KQ:088340
|
-0.254x |
|
TOUAX INH. EO 8
F:TOX
|
N/A |
|
TeraGo Inc
PINK:TRAGF
|
-0.263x |
|
iMBC Co.Ltd
KQ:052220
|
0.023x |
|
iCRAFT Co. Ltd
KQ:052460
|
-0.181x |
Annual Cash Flow Conversion Efficiency for Vivoryon Therapeutics N.V. (2011–2024)
The table below shows the annual cash flow conversion efficiency of Vivoryon Therapeutics N.V. from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €7.88 Million | €-19.17 Million | -2.433x | -196.88% |
| 2023-12-31 | €26.28 Million | €-21.54 Million | -0.820x | +0.32% |
| 2022-12-31 | €26.51 Million | €-21.79 Million | -0.822x | -20.93% |
| 2021-12-31 | €16.56 Million | €-11.26 Million | -0.680x | -27.23% |
| 2020-12-31 | €26.22 Million | €-14.01 Million | -0.534x | -96.41% |
| 2019-12-31 | €42.66 Million | €-11.61 Million | -0.272x | +95.22% |
| 2018-12-31 | €1.23K | €-6.99K | -5.686x | -318.73% |
| 2017-12-31 | €8.92K | €-12.12K | -1.358x | -67.77% |
| 2016-12-31 | €16.38K | €-13.26K | -0.809x | -7.50% |
| 2015-12-31 | €16.13K | €-12.15K | -0.753x | -13.56% |
| 2014-12-31 | €15.97K | €-10.59K | -0.663x | -132.85% |
| 2013-12-31 | €-4.22 Million | €-8.53 Million | 2.018x | +189.94% |
| 2012-12-31 | €5.37 Million | €-12.04 Million | -2.244x | -134.20% |
| 2011-12-31 | €14.95 Million | €-14.32 Million | -0.958x | -- |